[Experimental studies on the effect of the combination sulfamoxole/trimethoprim on the Toxoplasma infection of the mouse (author's transl)].
Albino mice infected with Toxoplasma gondii (virulent strain BK) were treated for 20 days with a combination of N1-[4,5-dimethyl-2-oxazolyl]-sulfanilamide (sulfamoxole) and 2,4-diamino-5-(3,4,5-trimethoxy-benzyl)-pyrimidine (trimethoprim) in the ratio of 5:1 (trial preparation CN 3123; Nevin, Supristol). By the suitable dosage the mortality rate could be reduced considerably. In contrast to the untreated controls no antibodies were formed. No cysts could be detected in the brains of treated animals. Compared with the combination of trimethoprim/sulfamethoxazole the combination of trimethoprim/sulfamoxole showed a slightly better effect.
D000818:Animals; D004338:Drug Combinations; D051379:Mice; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013423:Sulfamoxole / Q000627:therapeutic use*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*; D014295:Trimethoprim / Q000627:therapeutic use*
D004338:Drug Combinations; D014295:Trimethoprim; D013423:Sulfamoxole; D013420:Sulfamethoxazole
Experimentelle Untersuchungen über die Wirksamkeit der Kombination Sulfamoxol/Trimethoprim (CN 3123) auf die Toxoplasma-Infektion der weissen Maus